Beauty Farm Medical and Health Industry Inc. completed an on-market buyback of 60,000 ordinary shares on 15 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The shares were repurchased at prices between HKD 17.78 and HKD 18.00, for a volume-weighted average of HKD 17.94 per share, bringing the cash outlay to HKD 1.08 million.

Following the transaction, issued shares (excluding treasury shares) fell from 248.96 million to 248.90 million, while treasury shares increased from 2.63 million to 2.69 million. Total shares outstanding remained unchanged at 251.59 million.

The buyback was executed under the mandate approved on 27 June 2025, which authorises the company to repurchase up to 23.58 million shares. Including the latest purchase, 2.69 million shares—or 1.14 % of the company’s issued share capital at the time the mandate was granted—have been bought back under this authority, leaving approximately 20.89 million shares, or 8.86 % of the original mandate, still available.

Under Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 15 July 2026.

Director Li Yang confirmed that the repurchase complied with all applicable regulatory requirements and that no material changes have been made to the June 2025 explanatory statement previously filed with the Exchange.